← All FDA warning letters

FDA Warning Letter · #674310

AnuMed International, LLC — FDA Warning Letter (August 20, 2024)

Issued August 20, 2024Status: activeCenter for Drug Evaluation and Research (CDER)

In plain English

Unapproved drugs

FDA said products made or sold by AnuMed International, LLC, including semaglutide, are unapproved new drugs under federal law.

What it means for you

Unapproved drugs like these have not been reviewed by FDA for safety, quality, or effectiveness. A GLP-1 should come with a prescription and from a state-licensed pharmacy.

Drugs named:semaglutide

Primary Source

View the original FDA letter on fda.gov →

https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/anumed-international-llc-674310-08202024

Letter details

Company
AnuMed International, LLC
Letter number
#674310
Issue date
August 20, 2024
Subject
Finished Pharmaceutical/Unapproved New Drug/Adulterated/Misbranded

What FDA warning letters mean

A warning letter is FDA's principal means of telling a company that the agency considers something it's doing — a marketing claim, a manufacturing practice, a labeling choice — to violate the Federal Food, Drug, and Cosmetic Act. Companies typically have 15 working days to respond.

A warning letter is not a recall, a criminal charge, or a finding that the company has broken the law. It is the start of a regulatory conversation. FDA may issue a close-out letter once it is satisfied that the company has corrected the cited issues.

For compounded GLP-1 telehealth providers, the most common citations involve unapproved new drug claims, misbranding, and the use of bulk drug substances not on FDA's approved list under FDCA sections 503A and 503B.

What this letter means if you use compounded GLP-1s

A warning letter is not a recall, and it does not by itself mean a product you already have is unsafe, but it does mean the FDA found problems it expects AnuMed International, LLC to fix. Compounded GLP-1s are not FDA-approved, and the rules for selling them changed when the shortages ended; our explainer on where compounded semaglutide stands with the FDA now covers what is still allowed.

The products in this letter are ones FDA calls unapproved new drugs. For contrast, our semaglutide drug guide page shows the versions that went through FDA review, and which GLP-1s can be compounded explains where the rules draw the line.

Other warning letters in our database

View the full database →

Editorial Disclaimer

FDA warning letters are public regulatory communications and do not, on their own, indicate that a company has done anything illegal. Companies often respond to warning letters with corrective action, and many letters are eventually closed out. The full text of this letter is available on fda.gov via the link above.

Key terms, explained

New to GLP-1s? Tap any term for a quick, plain-English definition.